
Bram Verstockt, GuiCom Member
The latest ECCO Topical Review provides important, practice-oriented guidance on the increasingly recognised entity of drug-induced colitis (DIC), with a particular focus on immune checkpoint inhibitor (ICI)-related disease. DIC is described as a heterogeneous condition that can mimic Inflammatory Bowel Disease both clinically and histologically, making diagnosis challenging. Multiple patterns may coexist, ranging from acute and chronic inflammation to microscopic or ischaemic features, none of which are fully specific.




